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Background: Biliary tract cancer (BTC) is a highly lethal disease for which the best available therapy remains undeter-
mined. The mammalian target of rapamycin (mTOR) pathway is up-regulated in several cancers, including BTC, and pre-
clinical evidence indicates that mTOR inhibition may be effective in the treatment of BTC. We sought to evaluate the
activity and tolerability of the mTOR inhibitor RAD001—everolimus—in patients with BTC progressing after prior chemo-
therapy.
Patients and methods: This was an open-label, single-arm, phase II study (EUDRACT 2008-007152-94) conducted
in eight sites in Italy. Patients with locally advanced, metastatic or recurrent BTC progressing despite previous chemother-
apy received a daily oral dose of everolimus 10 mg administered continuously in 28-day cycles. The two primary end
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points were disease control rate (DCR) and objective response rate (ORR). Secondary end points were progression-free
survival (PFS), overall survival (OS) and time-to-progression (TTP).
Results: Thirty-nine patients were enrolled. The DCR was 44.7%, and the ORR was 5.1%. One patient showed a partial
response at 2 months and one patient showed a complete response sustained up to 8 months. The median (95% confi-
dence interval) PFS was 3.2 (1.8–4.0) months, and the median OS was 7.7 (5.5–13.2) months. The median TTP was
2.0 (1.7–3.7) months. Most common toxicities were asthenia (43.6%), thrombocytopenia (35.9%), pyrexia (30.8%) and
erythema, mainly of mild-to-moderate severity. Two patients required dose reduction due to adverse events.
Conclusion: Everolimus demonstrated a favourable toxicity profile and encouraging anti-tumour activity. Further trials
are needed to establish the role of everolimus in the treatment of BTC.EUDRACT 2008-007152-94.
Key words: advanced biliary tract cancer, everolimus, mTOR
introduction
Biliary tract cancer (BTC), which encompasses cholangiocarci-
noma (CC) and gallbladder carcinoma (GBC), is a disease with
high mortality, limited treatment options and few significant
improvements in the therapeutic strategy over the last 10–20
years. Currently, tumour resection is the only potential cure for
BTC. However, most BTCs are diagnosed at advanced stages,
when tumour is unresectable. Five-year survival rates are <5%–10%
for advanced BTC [1], and the median survival of patients with
advanced disease is frequently <1 year [2]. Chemotherapeutic
agents currently used for the treatment of BTC include gemcita-
bine, 5 fluorouracil (5-FU), mitomycin C and platinum analo-
gues [2]. Objective response rates (ORR) to most of these drugs
range from 0% to 40%, with no complete remissions [3]. In most
cases, treatment after disease progression consists of palliative
care, with only 25% of patients receiving further chemotherapy
[4]. More effective strategies for the treatment of BTC are needed
to improve the prognosis and quality of life (QoL) of BTC
patients.
RAD001 (everolimus) is a mammalian target of rapamycin
(mTOR) inhibitor currently indicated for the treatment of
advanced breast cancer, neuroendocrine tumours of pancreatic
origin and renal cell carcinoma [5]. The mTOR pathway, which
plays a key role in cell growth, proliferation and survival, is
known to be up-regulated in many cancer types, including
extrahepatic CC [6].
In transgenic mouse models of GBC, mTOR inhibition has
yielded promising results [7]. The mTOR status was found to be
an independent prognostic factor in patients with BTC, overall
survival being significantly shorter in patients with m-TOR-
positive tumours [8]. We undertook the present study to assess
the activity and tolerability of everolimus in patients with BTC
progressing after prior chemotherapy.
patients andmethods
study design
This was an open-label, single-arm, multicentre phase II study in eight sites
in Italy (EUDRACT 2008-007152-94). The study was conducted according
to ICH/GCP guidelines and the Declaration of Helsinki and approved by the
Ethic Committees of participating Centres. All patients provided written
informed consent.
eligibility criteria
Eligible participants were adult patients (age 18–75 years) with histologically
or cytologically confirmed locally advanced, metastatic or recurrent BTC
that had progressed despite previous chemotherapy and who had at least one
measurable site of disease according to the Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1 [9] and no indication to surgery or
radiotherapy for locally advanced disease. Only patients who had received
no more than one previous systemic chemotherapy regimen were enrolled.
Adjuvant chemotherapy and/or radiotherapy were not considered as first-
line chemotherapy. Further inclusion criteria are provided as supplementary
material, available at Annals of Oncology online.
treatment and dose modifications
Everolimus was administered orally at a daily dose of 10 mg continuously
(28-day cycles). Therapy was continued from day 1 until progression of
disease, unacceptable toxicity or discontinuation from study drug for any
other reason. Thereafter, patients were followed-up. Dose adjustments were
allowed in patients unable to tolerate the protocol-specified dosing schedule.
If toxicity was tolerable to the patient, the initial dose was maintained. Dose
reductions for toxicity were as follows: dose level 1, 5 mg daily; and dose
level 2, 5 mg every other day.
assessments
Baseline evaluations included a complete history and physical examination;
ECOG performance status; complete blood count, coagulation parameters,
biochemical measurements and fasting lipid profile; pregnancy test in
women of childbearing potential; electrocardiogram and chest X-ray.
Laboratory assessments were repeated every 2 weeks and at study end.
Tumour measurement was carried out by computed tomography and/or
magnetic resonance imaging of the abdomen, pelvis and chest before initi-
ation of treatment and subsequently every 8 weeks. Tumour response was
assessed using the RECIST criteria version 1.1 [9].
Safety was monitored throughout the study and for 28 days after discon-
tinuation of study drug. Adverse events (AEs) terms were classified by
Primary System Organ Class (SOC) according to the MedDRA thesaurus
version 12 [10]. All patients were assessed for toxicity as per the NCI
Common Toxicity Criteria, version 3. Survival was recorded every 2 months
for at least 1 year after enrolment of the last patient.
QoL was assessed with the EORTC QLQ-C30 questionnaire [11] at base-
line, every 8 weeks and at study end.
activity end points
The two primary activity end points were disease control rate (DCR)
and ORR, which were assessed hierarchically. The primary variable for
the definition of the DCR was the overall objective response (OOR) at the
8-week assessment, according to RECIST criteria. DCR was calculated as the
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proportion of patients with complete response (CR), partial response (PR)
or stable disease (SD) on the number of assessable patients.
The primary variable for defining the ORR was the best overall response
(CR or PR) achieved at any time during treatment, as per RECIST criteria
among patients who received at least one dose of study drug.
Secondary activity end points were progression-free survival (PFS),
overall survival (OS), and time-to-progression (TTP). PFS was defined as the
time from date of the first everolimus dose to the date of the event, defined
as the first documented progression or death due to any cause. In the case of
no event, PFS was censored at the date of last adequate tumour assessment.
OS was defined as the time from date of the first everolimus dose to the date
of death for any cause. If a patient was not known to have died, survival was
censored at the date of last contact. TTP was defined as time from date of the
first everolimus dose to the date of event (first documented progression or
death due to the underlying cancer). In the case of no event, time to progres-
sion was censored at the date of last adequate tumour assessment.
statistical analysis
A Simon optimum two-stage design was used [12]. The stopping rule was
based exclusively on DCR. A DCR of 5% or lower precluded further study,
whereas a DCR of 20% or higher would be considered sufficiently promising
to warrant further study. Assuming a type I error rate of 10% and a power of
90%, a total of 12 patients were enrolled in the first stage, which required at
least one patient achieving disease control to proceed to the second stage. An
additional 25 assessable patients would be enrolled in the second stage,
giving a total of 37 assessable patients. If ≥3 patients achieved disease
control, everolimus would be considered active and worthy of further testing.
Patients who experienced progression or death from progressive disease
before week 8 were considered as failures in the DCR. All data were consid-
ered for patients who had received at least one dose of study drug [intent-to-
treat (ITT) population]. Patient withdrawals due to AEs or toxicity before
the 8-week response evaluation were considered as treatment failures. The
Kaplan–Meier curves were estimated for the PFS, OS and TTP.
Continuous variables were summarized by descriptive statistics. Categorical
variables were summarized using counts of patients and percentages.
Comparisons were carried out with Student’s paired t-test. Statistical signifi-
cance was set at P < 0.05. Statistical analyses were carried out with SAS System
(version 9.2, Cary, NC).
results
patient characteristics
Thirty-nine patients were enrolled between January 2009 and
December 2011. Patients’ characteristics (ITT population) are
listed in Table 1. Thirty-seven patients (94.9%) had a histologic-
al or cytological diagnosis of CC, while two (5.1%) had GBC. At
diagnosis, 8 patients (20.5%) had stage II disease, 3 (7.7%) had
stage III and 28 (71.8%) had stage IV. Thirty-one (79.5%)
patients had ECOG 0, five (12.8%) ECOG 1 and three (7.7%)
ECOG 2. At study enrolment, all patients had received previous
chemotherapy. The combination of gemcitabine and oxaliplatin
(GEMOX) was the most common first-line chemotherapy
regimen.
treatment exposure
The median compliance was 92.9% (range 50–100%). The median
exposure to study drug was 67.5 days (range 15–674 days). Of the
39 assessable patients (ITT population), 36 discontinued the study
drug because of disease progression. One patient withdrew consent
after 12 weeks and two patients died for the onset of adverse
events after 8 weeks of treatment (deaths: 11 and 14 weeks).
activity
One patient was excluded from the analysis of DCR due to
missing data on tumour response at week 8. Of the 38 assessable
patients, one patient (2.6%) had a PR and 16 patients (42.1%)
showed SD (DCR 44.7%) at week 8 (supplementary Table S1,
available at Annals of Oncology online). Twenty-one patients
(55.3%) had disease progression at week 8. The ORR was 5.1%,
with one patient showing a PR at 2 months (59-year-old male
with GBC; PFS 8.5 months and OS 10.1 months) and one
patient showing CR at 4, 6 and 8 months (57-year-old male with
intrahepatic CC; PFS 10 months and OS 17 months).
The median (95% CI) PFS in the ITT population was 3.2
(1.8–4.0) months (Figure 1A). The proportion of progression-
free patients was 51.3% (34.8–65.6) at 3 months, 28.2% (15.3–
42.7) at 6 months, 5.1% (1.0–15.2) at 12 months and 0% (NA)
at 18 months.
The median OS was 7.7 (5.5–13.2) months (Figure 1B). One
patient was censored from the OS analysis. The proportion of
patients alive was 79.5% (63.1–89.2) at 3 months, 56.4% (39.6–
70.2) at 6 months, 32.4% (18.4–47.3) at 12 months and 10.8%
(3.4–23.0) at 18 months (supplementary Table S2, available at
Annals of Oncology online). Percentile analysis showed that one-
quarter of patients had an OS >15.3 months.
The median TTP in the ITT population was 2.0 (1.7–3.7)
months.
safety
The total number of AEs in the safety population (n = 39) was
384; 261 of which (67.9%) were considered as treatment-related
(Table 2). Overall, the most common AEs were asthenia
(43.6%), thrombocytopenia (35.9%), pyrexia (30.8%) and
Table 1. Baseline demographic and clinical characteristics (safety
population, n = 39)
Characteristic Value
Age (years), median (range) 63 (36–75)
Gender, n (%)
Male 17 (43.6)
Female 22 (56.4)
Stage at diagnosis, n (%)
II 8 (20.5)
III 3 (7.7)
IV 28 (71.8)
ECOG performance status, n (%)
0 31 (79.5)
1 5 (12.8)
2 3 (7.7)
Previous surgery for cancer, n (%)
Yes 21 (53.8)
No 18 (46.2)
Previous radiotherapy, n (%)
Yes 6 (15.4)
No 33 (84.4)
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erythema (23.1%). Grade 1 AEs were reported in 33 patients
(86.6%), grade 2 AEs in 34 patients (87.2%), grade 3 AEs in 20
patients (51.3%) and grade 4 AEs in 13 patients (33.3%).
The most common grade 3–4 toxicities were hyperbilirubi-
naemia (15.4%), elevated alanine aminotransferase (12.8%),
hypocalcaemia (12.8%), elevated alkaline phosphatase (10.3%),
thrombocytopaenia (10.3%) and hyperglycaemia (10.3%). In
total, 21 grade 4 AEs were reported; six of these, occurring in
three patients (23.1% of patients with grade 4 toxicity), were
classified as probably (thrombocytopenia, pneumonia, anorexia,
nausea and vomiting), or certainly (stomatitis) related to study
drug. Two patients (5.1%) died due to an AE (both for cach-
exia), but those events were not considered drug-related. Dose
reduction due to AEs was required in two patients (one for neu-
tropenia and one for hypersensitivity).
QoL and performance status
Data on QoL at baseline and study end were available for 19
patients (48.7%). There was a trend towards a decrease from
baseline in global health status, physical functioning, role func-
tioning and emotional functioning and a statistically significant,
moderate improvement in fatigue (P = 0.039). A small but sign-
ificant (P = 0.030) deterioration was observed in the pain sub-
scale. No changes were observed in the remaining QLQ-C30
items. With respect to PS, at study end, data were available for
26 patients, 22 of whom (84.6%) had ECOG 0–2 and 4 (15.4%)
had ECOG ≥3.
discussion
BTC is a highly lethal cancer for which the best available chemo-
therapy remains to be determined. In a large meta-analysis of
clinical trials of chemotherapy in advanced BTC, the overall OS
for all patients included in the survival analysis (n = 1543) was
8.2 months, with a tumour control rate of 57.3% (n = 2386) [13].
At present, gemcitabine- and platinum-containing regimens
appear to be the most effective first-line treatment for advanced
BTC, with reported median OSs of 9.5–11.7 months [14]. In
contrast, there is an urgent need to establish an effective second-
line treatment to improve survival of BTC patients.
The results of the present study support the role of mTOR as
a potential therapeutic target in BTC. The 44.7% DCR at 8
weeks, along with the median PFS, TTP and OS of ∼3, 2 and 7.2
months, respectively, indicate that everolimus is active in
patients with BTC progressing despite previous chemotherapy.
Noteworthy, OS data and the percentile analysis seem to suggest
that patients who are still alive after the first months of therapy
present a prolonged OS, with 32.4% and 25% of patients still
alive after 12 and 15 months of therapy, respectively. This
finding suggests that proper selection of patients eligible to ever-
olimus therapy could maximize the clinical benefits of the drug.
The identification of predictive biomarkers of response to evero-
limus could help optimize the management of BTC patients,
and could be the aim of future studies.
Previously evaluated second-line chemotherapy regimens
include the combination of 5-FU, doxorubicin and mitomycin
C, gemcitabine as a single agent and the oral fluoropyrimidine
S-1 [15–17]. In these trials, the average DCR was ∼43%, with a
median TTP of ∼2 months, a median OS of 4–7 months and no
patient showing CR. Recently, a retrospective study analysed the
efficacy of second-line chemotherapy in advanced BTC, report-
ing DCRs and SD of 43% and 34%, respectively, and the median
PFS and OS of 2.8 and 7.5 months, respectively [4].
Although a comparison with previous studies is difficult due
to different design and patient populations, in the present study,
everolimus treatment resulted in longer OS when compared
with previous trials on second-line chemotherapy, complete
tumour response in one patient at 4, 6 and 8 months and partial
response in one patient at 2 months. Furthermore, 42.1% of
patients had SD at 2 months.
Targeting the mTOR pathway may represent a novel and ef-
fective strategy for the treatment of BTC. Although the genetics
of BTC are highly heterogeneous, there is evidence that the
mTOR pathway is involved either directly or indirectly in CC
tumorigenesis [18], and activation of this pathway may negative-
ly impact the prognosis of patients with BTC [8]. Inhibition of
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Figure 1. The Kaplan–Meier plots of progression-free survival (A) and overall survival (B) in the ITT population (n = 39).
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Table 2. Total adverse events by system organ class (SOC) and severity and proportion of adverse events with a suspected relationship with everolimus
experienced by ≥5% of patients (safety population, n = 39)
Adverse event n (%) G1–G2 G3–G4 Drug-related
Total number of adverse events 384 347 37 261
Number of patients with at least one adverse eventa 39 (100) 34 (87.2) 20 (51.3) 36 (92.3)
General disorders and administration site conditionsa 27 (69.2) 25 (64.1) 6 (15.4) 19 (48.7)
Asthenia 17 (43.6) 14 (35.9) 3 (7.7) 12 (30.8)
Pyrexia 12 (30.8) 11 (28.2) 1 (2.6) 7 (17.9)
Mucosal inflammation 8 (20.5) 7 (17.9) 1 (2.6) 7 (17.9)
Peripheral oedema 8 (20.5) 8 (20.5) — 3 (7.7)
Condition aggravated 2 (5.1) — 2 (5.1) —
Fatigue 2 (5.1) 2 (5.1) — 2 (5.1)
Pain 2 (5.1) 2 (5.1) — —
Chest pain 2 (5.1) 2 (5.1) — —
Gravitational oedema 2 (5.1) 2 (5.1) — 2 (5.1)
Gastrointestinal disordersa 26 (66.7) 31 (79.5) 6 (15.4) 19 (48.7)
Abdominal pain 8 (20.5) 5 (12.8) 3 (7.7) 3 (7.7)
Nausea 8 (20.5) 7 (17.9) 1 (2.6) 6 (15.4)
Stomatitis 8 (20.5) 8 (20.5) — 8 (20.5)
Vomiting 6 (15.4) 5 (12.8) 1 (2.6) 4 (10.3)
Ascites 5 (12.8) 4 (10.3) 1 (2.6) 2 (5.1)
Diarrhoea 4 (10.3) 4 (10.3) — 3 (7.7)
Gastrointestinal obstruction 3 (7.7) — 3 (7.7) —
Constipation 2 (5.1) 2 (5.1) — —
Upper abdominal pain 2 (5.1) 2 (5.1) — —
Blood and Lymphatic system disordersa 21 (53.8) 21 (53.8) 3 (7.7) 21 (53.8)
Thrombocytopenia 14 (35.9) 13 (33.3) 1 (2.6) 14 (35.9)
Anaemia 6 (15.4) 6 (15.4) — 6 (15.4)
Neutropenia 6 (15.4) 5 (12.8) 1 (2.6) 6 (15.4)
Leukopenia 2 (5.1) 1 (2.6) 1 (2.6) 2 (5.1)
Thrombocythaemia 2 (5.1) 1 (2.6) 1 (2.6) 2 (5.1)
Skin and subcutaneous tissue disordersa 17 (43.6) 18 (46.2) — 16 (41.0)
Erythema 9 (23.1) 9 (23.1) — 9 (23.1)
Skin toxicity 2 (5.1) 2 (5.1) — 2 (5.1)
Metabolism and nutrition disordersa 15 (38.5) 16 (41.0) 3 (7.7) 9 (23.1)
Anorexia 7 (17.9) 6 (15.4) 1 (2.6) 3 (7.7)
Hypertriglyceridaemia 3 (7.7) 3 (7.7) — 3 (7.7)
Cachexia 2 (5.1) — 2 (5.1) —
Hyperglycaemia 2 (5.1) 2 (5.1) — 2 (5.1)
Hypercholesterolaemia 2 (5.1) 2 (5.1) — 2 (5.1)
Hyponatraemia 2 (5.1) 2 (5.1) — —
Investigationsa 14 (35.9) 18 (46.2) 2 (5.1) 12 (30.8)
Elevated alkaline phosphatase 6 (15.4) 5 (12.8) 1 (2.6) 4 (10.3)
Elevated alanine amonotransferase 5 (12.8) 5 (12.8) — 4 (10.3)
Elevated aspartate aminotransferase 5 (12.8) 4 (10.3) 1 (2.6) 4 (10.3)
Weight loss 5 (12.8) 5 (12.8) — 3 (7.7)
Elevated bilirubin 3 (7.7) 1 (2.6) 2 (5.1) —
Hypokalaemia 2 (5.1) 2 (5.1) — 2 (5.1)
Elevated γ-glutamyltransferase 2 (5.1) 1 (2.6) 1 (2.6) 2 (5.1)
Respiratory, thoracic and mediastinal disordersa 14 (35.9) 17 (43.6) — 8 (20.5)
Cough 7 (17.9) 7 (17.9) — 3 (7.7)
Dyspnoea 5 (12.8) 5 (12.8) — 2 (5.1)
Epistaxis 4 (10.3) 4 (10.3) — 4 (10.3)
Rales 2 (5.1) 2 (5.1) — 2 (5.1)
Hepatobiliary disordersa 11 (28.2) 8 (20.5) 4 (10.3) 5 (12.8)
Hepatomegaly 6 (15.4) 5 (12.8) 1 (2.6) 3 (7.7)
Jaundice 3 (7.7) 1 (2.6) 2 (5.1) —
Hyperbilirubinaemia 2 (5.1) 1 (2.6) 1 (2.6) 2 (5.1)
Continued
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mTOR has antiproliferative effects on different BTC cell lines
in vitro, and is known to reduce angiogenesis by diminishing
vascular endothelial growth factor (VEGF) [19, 20]. Everolimus
was able to induce a 50% reduction in cell growth of human
extrahepatic CC and GBC cell lines, and the combination of
everolimus with gemcitabine had the strongest synergistic effect
on extrahepatic cell lines when compared with the combination
of gemcitabine with a VEGF-inhibitor, allowing a significant re-
duction in the median gemcitabine dose [21]. A single-arm,
phase I study designed to determine the maximally tolerated
dose of everolimus plus gemcitabine and to obtain pilot data on
toxicity and efficacy outcomes in patients with advanced refrac-
tory CC/GBC is currently ongoing [22].
In the present study, drug-related toxicity was observed in
92.3% of patients, with a spectrum of toxicities that was similar
to that observed with everolimus in other cancers [23, 24].
Overall, everolimus had not any marked effect on QoL.
The patient sample in this study was relatively small.
However, this reflects the modest incidence of the disease in the
overall population; in addition, many BTC patients die or
require only supportive care after the first-line treatment. We
used the RECIST criteria to evaluate DCR, PFS and TTP. These
criteria may not take into account the cytostatic effect of everoli-
mus, since they are more focused on variations in tumour size.
Lastly, we did not report data on immunohistochemistry (IHC)
assessments: IHC samples were available only for 11 patients,
all treated in a single Centre (Istituto Nazionale Tumori,
Milan, Italy) and therefore not representative of the entire study
population.
In conclusion, everolimus demonstrated a favourable toxicity
profile and promising anti-tumour activity as a second-line therapy
in BTC patients. Larger trials are needed to better establish the
role of everolimus in the treatment of BTC and identify prog-
nostic biomarkers predictive of response to targeted therapies.
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appendix
Further eligibility criteria.
inclusion criteria
Eastern Cooperative Oncology Group (ECOG) performance
status 0–2; life expectancy >12 weeks; adequate organ function,
as defined by normal complete blood count, liver function tests
[total serum bilirubin ≤1.5×upper limit of normal (ULN);
serum aspartate transaminase and serum alanine transaminase
≤2×ULN (<5 times the ULN for patients with liver metastases),
alkaline phosphatase <2.5×ULN (unless bone metastases were
present in the absence of any liver disorders) and renal function;
no major surgery, radiotherapy or chemotherapy within 4 weeks
before study entry.
exclusion criteria
Therapy with a VEGF inhibitor (VEGFi) within 4 weeks before
study entry, previous therapy with mTOR inhibitors (sirolimus,
temsirolimus, everolimus), known hypersensitivity to everoli-
mus or other mTOR inhibitors, chronic systemic treatment with
corticosteroids or other immunosuppressive agents, known HIV
or active infections, autoimmune hepatitis, active bleeding di-
athesis, severe or uncontrolled medical conditions, congestive
heart failure or angina pectoris, history of relevant neurological
or psychiatric disorders, past or current history of neoplasm
other than curatively treated non-melanoma skin cancer or car-
cinoma in situ of the uterine cervix; metastatic involvement of
the central nervous system; malabsorption syndrome or any
other disorders that could affect gastrointestinal absorption;
pregnancy or breastfeeding.
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